GOLM1 and metabolic dysfunction-associated steatotic liver disease: By establishing a pathological role for elevated GP73 in non-obese NAFLD, our findings not only provide convincing evidence that elevated hepatic expression of GP73 can trigger non-obese NAFLD development in a GAP activity-dependent manner, but also provide a potent therapeutic target for blocking non-obese NAFLD development (Supplementary Fig. 7).